Bleomycin for Injection, USP

**WARNINGS**

Avoid the possibility of anaphylactic reaction, lymphoma patients should be observed carefully and frequently during and after therapy. It is recommended that Bleomycin for Injection be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate diagnostic procedures recommended in the guidelines are necessary or appropriate.

**INDICATIONS AND USE**

Bleomycin for Injection is contraindicated in patients who have demonstrated a hypersensitivity or an anaphylactic reaction to it.

**ADVERSE REACTIONS**

Pulmonary toxicities may occur at lower doses. Pulmonary toxicities occur in 10% of treated patients. In approximately 1%, the nonspecific toxicities are severe and often fatal. These toxicities may occur, however, at any time after initiation of therapy.

**DIAGNOSTIC AND THERAPEUTIC MEASURES**

If the possibility of an anaphylactic reaction, lymphoma patients should be observed carefully and frequently during and after therapy. Appropriate diagnostic procedures recommended in the guidelines are necessary or appropriate.

**REFERENCES**

1. National Study Commission on Cytotoxic Exposure-Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, ScD, Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Bay State Road, Boston, MA 02215.


6. Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Bay State Road, Boston, MA 02215.
